Valneva's Lyme Vaccine VLA15 Shows Strong Phase 2 Booster Results With Favorable Safety
(RTTNews) - Valneva SE (VALN) announced positive final immunogenicity and safety data from its Phase 2 study, VLA15-221, evaluating the Lyme disease vaccine candidate VLA15. The study results...
Nasdaq News: Markets·17d ago